Ambu A/S (AMBU-B.CO)
- Previous Close
120.30 - Open
123.90 - Bid 120.50 x --
- Ask 120.60 x --
- Day's Range
120.00 - 125.00 - 52 Week Range
101.70 - 154.60 - Volume
638,203 - Avg. Volume
437,340 - Market Cap (intraday)
32.1B - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
98.77 - EPS (TTM)
1.22 - Earnings Date May 7, 2025
- Forward Dividend & Yield 0.38 (0.32%)
- Ex-Dividend Date Dec 5, 2024
- 1y Target Est
140.46
Ambu A/S, a medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, and displaying units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products; airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, resuscitators, video laryngoscopes, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
www.ambu.comRecent News: AMBU-B.CO
View MorePerformance Overview: AMBU-B.CO
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMBU-B.CO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMBU-B.CO
View MoreValuation Measures
Market Cap
32.05B
Enterprise Value
32.02B
Trailing P/E
99.42
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.72
Price/Book (mrq)
5.53
Enterprise Value/Revenue
5.67
Enterprise Value/EBITDA
39.98
Financial Highlights
Profitability and Income Statement
Profit Margin
5.77%
Return on Assets (ttm)
6.70%
Return on Equity (ttm)
5.81%
Revenue (ttm)
5.65B
Net Income Avi to Common (ttm)
326M
Diluted EPS (ttm)
1.22
Balance Sheet and Cash Flow
Total Cash (mrq)
588M
Total Debt/Equity (mrq)
9.73%
Levered Free Cash Flow (ttm)
264.75M